US-headquarted Synthetech, Inc., a fine chemicals company, specializes in organic synthesis, biocatalysis, and chiral technologies. Its products are used in the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at various stages of a customer’s clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular, and other diseases.

Synthetech engaged Bryan, Garnier & Co to conduct a comprehensive review of strategic alternatives aimed at enhancing shareholder value. Strategic alternatives it considered included the execution of its operating plan, the sale or acquisition of assets or businesses, partnering or other collaboration agreements or arrangements, a merger or sale of the company or other strategic transactions.


About Grace

Grace is a leading global supplier of catalysts and other products to petroleum refiners; catalysts for the manufacture of plastics; silica-based engineered and specialty materials for a wide range of industrial applications; sealants and coatings for food and beverage packaging, and specialty chemicals, additives and building materials for commercial and residential construction. Founded in 1854, Grace has operations in over 40 countries.

Discover Grace

Gregg Blake

Investment Banking

Gregg Blake photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }